Otsuka

#1855

Rank

$7.72B

MarketCap JP

JP Japan

Country

Summary
Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a conditioning beverage; EQUELLE and EQUELLE Gelée, which supports women's health and beauty; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; and OS-1, an oral rehydration solution. In addition, the company offers soft drinks, food products, and wines; clinical testing and medical equipment; cosmetics; warehousing and transport services; chemical products; travel agency services; analysis and measurement equipment; pharmaceutical intermediates; testing equipment, such as vehicle headlight testers; synthetic resin molded products; venture capital services; paper products; artificial turf; ceramic boards, ceramic board masterpiece arts, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; IT solution services; insecticides and toiletry products; and flaky titanate and special compounds. Further, it provides infusion and clinical nutrition products; Xenotransplantation products; hydrazine; plant-based food products, including cheese alternatives, dressings, and desserts; stable isotopes; software and services to enhance management of mental healthcare systems; products for urinary tract health; potassium titanate; bio-pesticides; functional and dietetic foods; spring and mineral water; industrial chemicals; polyolefin foams; anticancer drugs; and adhesive tapes. Additionally, the company operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.

History

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.

Otsuka Pharmaceutical Co. LTD Holdings

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine . Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.In July 2017, they bought DaiyaIn July 2018, Otsuka agreed to acquire Visterra for $430 million cash.


Mission
To prevent and alleviate human suffering in the face of emergencies by mobilizing the power of volunteers and the generosity of donors."

Vision
Improve every day

Key Team

Mr. Masayuki Kobayashi (Exec. Director)

Mr. Makoto Inoue (Exec. Director)

Ms. Yuko Makino (CFO & Exec. Director)

Tsuyoshi Nakamura (VP and Head of Fin. & Accounting)

Akiko Ryu (Sr. VP & Director of Human Resource Planning Department)

Mr. Shuichi Takagi (MD, CSO & Director)

Chiaki Sakurai (Sr. VP of Nutraceutical Bus., Global Strategy & Planning Headquarters)


Recognition and Awards
Otsuka has won numerous awards and recognition over the years. Among the most notable distinctions, Otsuka was recognized as one of the “Best Corporate Citizens in Japan” in 2017, and was awarded the “Silver award” in the Kantar TNS Performance Excellence Index in 2017.

References
Otsuka
Leadership team

Mr. Tatsuo Higuchi (CEO, Pres & Representative Director)

Ms. Noriko Tojo (Exec. Director)

Mr. Yoshiro Matsuo (Exec. Deputy Pres & Director)

Products/ Services
Biotechnology, Health Care, Manufacturing, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Tokyo, Tokyo, Japan
Established
1964
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
4768.T
Social Media
Fri Mar 01 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium